objective(s):multidrug resistance (mdr) of cancer cells is a major obstacle to successful chemotherapy. overexpression of breast cancer resistance protein (bcrp) is one of the major causes of mdr. in addition, it has been shown that pi3k/akt signaling pathway involves in drug resistance. therefore, we evaluated the effects of novel approaches including sirna directed against bcrp and targeted t...

 Poorto intermediate-risk acute myeloid leukemia (AML) in remission  AML that is refractory to standard induction chemotherapy but can be brought into CR with intensified induction chemotherapy  AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensified induction chemotherapy; or  AML in patients, who have relapsed following a prior autologou...

PURPOSE The value of adding induction chemotherapy to chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) remains controversial, yet high-risk patients with LA-NPC have poor outcomes after chemoradiotherapy. We aimed to assess the survival benefits of induction chemotherapy in stage IVa-b NPC. PATIENTS AND METHODS A total of 602 patients with stage IVa-b NPC treated...

Eukaryotic cells, from yeast to mammals, respond and adapt to environmental and microenvironmental stressors by evolutionary conserved multicomponent endogenous systems that utilise a network of signal transduction pathways to regulate the adaptive and protective phenotype. The balance between cell survival and cell death is decisive for sensitivity or resistance to DNA-damaging chemotherapeuti...

Background: Hyperglycemia is one of the most complications of corticosteroid and asparaginase during induction phase of chemotherapy in children suffering from acute lymphoblastic leukemia (ALL). This study was carried out to evaluate the incidence of hyperglycemia and associated risk factors during chemotherapy induction phase at Amirkola Children's Hospital. Materials and Methods: In this c...

 poorto intermediate-risk AML (Acute Myeloid Leukemia) in first complete remission (CR1) (see Policy Guidelines for information on risk stratification); or  AML that is refractory to standard induction chemotherapy, but can be brought into CR with intensified induction chemotherapy; or  AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensifie...